A feature regarding cataract surgery includes expertise from Mitchell Brinks, M.D., M.P.H., about procedure benefits, risks and outcomes.

OHSU’s involvement in a joint project to increase Native American representation in medical and health science schools is featured.

OHSU’s Mission Control command center, which uses machine learning technology to ensure more patients receive the care they need at OHSU, is featured in a story about how technology could advance the future of health care.

In a story about a new metric that could help predict whether patients will respond to immunotherapies, Vinay Prasad, M.D., M.P.H., says: “Even in cancers where immunotherapy has no FDA approvals, patients ask for it, in part because they’ve heard about it on the news or TV. But, we have also seen many patients for whom immunotherapy has caused devastating side effects.”

A team of OHSU researchers shared early results from a blood-based cancer detection and mutation pilot study that uses cancer patients' radiation treatments to boost tumor DNA levels for easier detection and sequencing.

In a story about ongoing debate over the effectiveness and safety of the new FDA-approved antidepressant nasal spray esketamine, Erick Turner, M.D., says: “In the case of esketamine, you have this unmet need, this drum that gets pounded over and over again: People are dying and we don't have anything for them. But that actually makes the data all the more disappointing”.

New research conducted at the OSU/OHSU College of Pharmacy determines that gene-infused nanoparticles that include plant-based relatives of cholesterol are more effective when combatting disease.

Rochelle Williams-Belizaire speaks about Susan G. Komen’s African-American Advisory Council, aimed to glean input on breast cancer initiatives from the African-American community. She says: “Despite relative screening efforts and the incidents for the disease, for some reason African-Americans are more susceptible.”

Tim and Mary Boyle give $10 million to OHSU to support joint UO-OHSU center for biomedical data science. Danny Jacobs, M.D., M.P.H., FACS, says: “Our partnership is exciting because it will contribute to OHSU’s efforts to advance innovation, science, health and well-being through our signature, nationally distinguished programs in cancer, but also in many other disciplines. The Boyles’ investment will accelerate our progress by broadening, enhancing and expanding our capacity”.

A new study led by Richard Maziarz, M.D., finds adult lymphoma patients treated with CAR-T therapy showed marked improvement on a variety of self-reported quality of life measures.